Dow Jones

38 711,29

0,36%

DAX

Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.

S'inscrire

Accueil
Investir
Actions
Etats-Unis
NASDAQ
Peregrine Pharmaceuticals Inc. (MM) (PPHMD)
Peregrine Pharmaceuticals Inc. (MM) (PPHMD) Actualités

PPHMD

Peregrine Pharmaceuticals Inc. (MM) (PPHMD)

Peregrine Pharmaceuticals Inc. (MM)

De:

Actualités Réglementées

Mots clefs:

Trier par:

Actualités Non-réglementées

Showing the most relevant articles for your search:NASDAQ:PPHMD

Date	Heure	Source	Titre	Symbole	Société
29/03/2019	23h42	Business Wire	Announcing VanEck Vectors ETFs’ March 2019 Distributions	NASDAQ:PPHMD	Peregrine Pharmaceuticals Inc. (MM)
27/12/2018	00h37	Business Wire	Announcing VanEck Vectors Equity ETFs December 2018 Distribution	NASDAQ:PPHMD	Peregrine Pharmaceuticals Inc. (MM)
17/10/2018	17h48	Business Wire	VanEck Launches ESPO, ETF Focused on Fast Growing Video Game and eSports Industry	NASDAQ:PPHMD	Peregrine Pharmaceuticals Inc. (MM)
29/09/2018	00h03	Business Wire	Announcing VanEck Vectors Equity ETFs’ September 2018 Distributions	NASDAQ:PPHMD	Peregrine Pharmaceuticals Inc. (MM)
30/06/2018	00h15	Business Wire	Announcing VanEck Vectors Equity ETFs June 2018 Distributions	NASDAQ:PPHMD	Peregrine Pharmaceuticals Inc. (MM)
29/03/2018	23h58	Business Wire	Announcing VanEck Vectors Equity ETFs March 2018 Distributions	NASDAQ:PPHMD	Peregrine Pharmaceuticals Inc. (MM)
10/11/2009	15h30	PR Newswire (US)	New Study in Clinical Cancer Research Shows Therapeutic Promise of Peregrine's Bavituximab With Radiation in a Lethal Brain Canc	NASDAQ:PPHMD	Peregrine Pharmaceuticals Inc. (MM)
04/11/2009	20h17	PR Newswire (US)	Peregrine Pharmaceuticals Awarded Second Broad U.S. Patent for Anti-Viral Applications of Phospholipid-Targeting Antibodies	NASDAQ:PPHMD	Peregrine Pharmaceuticals Inc. (MM)
03/11/2009	21h00	PR Newswire (US)	Peregrine Pharmaceuticals Regains Full Compliance With Nasdaq Continued Listing Requirements	NASDAQ:PPHMD
27/10/2009	13h17	Edgar (US Regulatory)	Current report filing (8-K)	NASDAQ:PPHMD	Peregrine Pharmaceuticals Inc. (MM)
23/10/2009	23h34	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:PPHMD	Peregrine Pharmaceuticals Inc. (MM)
21/10/2009	15h30	PR Newswire (US)	Peregrine Pharmaceuticals Reports 61% Objective Response Rate in 46-Patient Bavituximab Phase II Trial in Advanced Breast Cancer	NASDAQ:PPHMD
19/10/2009	15h30	PR Newswire (US)	Peregrine Pharmaceuticals Appoints Former Genentech Senior Executive Dr. Robert Garnick as Head of Regulatory Affairs	NASDAQ:PPHMD
19/10/2009	14h30	PR Newswire (US)	Peregrine Pharmaceuticals 1:5 Reverse Stock Split Takes Effect	NASDAQ:PPHMD